The Department of Veterans Affairs (VA) is soliciting quotes for Contingency Pharmacy Compounding Products-Services for the Central Arkansas Veterans Healthcare System. This is an unrestricted combined synopsis/solicitation, 36C25626Q0026, prepared under FAR subpart 12.6 and FAR Part 13.5. The NAICS code is 325412 with a 1300-employee size standard. The period of performance is from December 26, 2025, to December 25, 2030. Questions are due by October 28, 2025, 10:00 AM CST, and quotes by November 7, 2025, 10:00 AM CST, both to be submitted via email to anthony.marion2@va.gov. The solicitation incorporates various FAR and VAAR clauses, including instructions for offerors and evaluation factors.

This combined synopsis/solicitation (36C25626Q0026) is for commercial items, specifically compounding hazardous chemotherapy agents for the Central Arkansas Veterans Healthcare System (CAVHS) in Little Rock, AR. The solicitation is unrestricted, with NAICS code 325412 and a size standard of 1300 employees. The period of performance is from December 26, 2025, to December 25, 2030, with a base year and four option years. Quotes are due by 10:00 AM CST on November 7, 2025, and questions must be submitted by 10:00 AM CST on October 28, 2025, both via email to Anthony Marion at anthony.marion2@va.gov. The contractor must be a licensed compounding pharmacy, experienced in hazardous chemotherapy, FDA 503A compliant, and meet USP 797 and 800 standards. Services include providing all necessary agents and devices, with orders submitted by 11 AM CST and delivery by 9 AM the following day. The contractor must also provide certification reports and a contingency plan. The document includes a comprehensive list of applicable FAR and VAAR clauses, as well as a detailed list of chemotherapy agents and medical supplies.

This document, "Attachment 1-Pharmacy Benefits Management Services (VHA PBM) Evaluation of Outsourced 503A Compounding Pharmacy," outlines the rigorous evaluation criteria for outsourced 503A compounding pharmacies seeking to provide services to Veterans Health Administration Medical Centers (VAMCs). It details regulatory, procedural, quality assurance, and personnel competency requirements. Key areas of evaluation include active pharmacy and shipping licenses, adherence to USP <795>, <797>, and <800> standards, HIPAA compliance, and accreditation. The document also scrutinizes the sourcing of active pharmaceutical ingredients, DEA registration for controlled substances, and staff licensure. Procedural requirements cover documentation of CSP preparation, adverse reaction management, aseptic manipulations within ISO Class 5 environments, and specific Beyond-Use Dates (BUDs). Stringent cleaning protocols for sterile environments and comprehensive personnel training, including media-fill testing and gloved fingertip/thumb sampling, are mandated. Finally, the document emphasizes finished preparation release checks and a formal quality assurance program that includes immediate notification of product recalls or compromising situations. This comprehensive framework ensures that outsourced compounding pharmacies meet high safety, quality, and regulatory standards for VAMCs.

This government file outlines a Blanket Purchase Agreement (BPA) for Contingency Pharmacy Compounding Products/Services for Hazardous Drugs. The contractor will provide compounding services for hazardous chemotherapy agents and related items like IV tubing, closed system drug transfer devices, and transportation, all on an as-needed, patient-specific basis. The document lists numerous hazardous drugs (e.g., Abraxane, Actemra, Acyclovir Sodium, Adcetris, Alimta, Arsenic Trioxide, Avastin, AzaCITIDine, Bendamustine HCl, Bleomycin Sulfate, Bortezomib, CARBOplatin, CISplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, DACTINomycin, Darzalex, DAUNOrubicin HCl, Decitabine, DOCEtaxel, DOXOrubicin HCl, Ellence, Enhertu, Erbitux, Etoposide, Fluorouracil, Folotyn, Fosaprepitant, Fulvestrant, Ganciclovir Sodium, Gazyva, Gemcitabine HCl, Granisetron HCl, Halaven, Herceptin, Herzuma, Idamycin PFS, Ifosfamide, Imfinzi, Imjudo, Irinotecan HCl, Istodax, Jemperli, Jevtana, Kadcyla, Kanjinti, Keytruda, Kyprolis, Leucovorin Calcium, Mesna, Mesnex, Methotrexate Sodium, MitoMYcin, MitoXANTRONE HCl, Mvasi, Mylotarg, Navelbine, Ocrevus, Onivyde, Opdivo, Oxaliplatin, PACLitaxel, PEMEtrexed Disodium, Perjeta, Phesgo, Polivy, Rituxan, Ruxience, Skyrizi, Tecentriq, Temsirolimus, Tepezza, Topotecan HCl, Trazimera, Truxima, Tysabri, Vectibix, Velcade, VinBLAStine Sulfate, VinCRIStine Sulfate, Vinorelbine Tartrate, Vyepti, Yervoy, Zepzelca, Zirabev), along with various medical supplies such as access devices, bags, adapters, extension sets, filters, and syringes. It also specifies dispensing fees for different services and includes Product or Service Code 6505 (Drugs and Biologicals) and NAICS Code 325412 (Pharmaceutical Preparation Manufacturing) with a size standard of 1300. The BPA establishes a Not to Exceed amount for each year, with invoicing based on utilized contract line item numbers (CLINs).